IP Library › Granted Patent US 11,076,785
Granted Patent B2
US 11,076,785 · App. 15/681,345 · Granted Aug 3, 2021

Method and apparatus for providing data processing and control in a medical communication system

Inventors: Gary Alan Hayter (Oakland, CA); Geoffrey V. McGarraugh (Bodega Bay, CA); Kenneth J. Doniger (Menlo Park, CA)
Assignee: Abbott Diabetes Care Inc.
A61B5/1486A61B5/002A61B5/0008A61B5/0022A61B5/1451A61B5/1473A61B5/14532A61B5/14546A61B5/4845A61B5/7275G16H40/63A61B2560/0223A61B2560/0242A61B2560/0276G16H15/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,076,785
App. No.
15/681,345
Granted
Aug 3, 2021
Kind
B2
Abstract

Methods and apparatus for providing data processing and control for use in a medical communication system are provided.

Claims (38)

1. An apparatus, comprising:

a data communication unit configured to wirelessly receive data corresponding to a monitored analyte level, the data generated using analyte sensor signals from an in vivo analyte sensor positioned in contact with biofluid under a skin surface, the received data including analyte data indicative of the monitored analyte level and one or more error indicators generated by the analyte sensor in response to detection of an error condition during measurement;

a memory device configured to store the received data; and

a data processing unit operatively coupled to the data communication unit and the memory device, the data processing unit configured to:

determine the monitored analyte level from the received analyte data;

determine one or more valid data points over a period of time based on the received data and the one or more error indicators;

determine a number of the error indicators received over the period of time;

and

determine a rate of change of the monitored analyte level based on the one or more valid data points when the number of the one or more error indicators received over the period of time are less than a predetermined amount.

2. The apparatus of claim 1 , wherein the biofluid is interstitial fluid.

3. The apparatus of claim 1 , wherein the analyte is either lactate or glucose.

4. The apparatus of claim 1 , wherein the data communication unit is configured to wirelessly receive the data corresponding to the monitored analyte level using a communication protocol, the communication protocol being one of an RF communication protocol, an infrared communication protocol, an 802.11x wireless communication protocol, or an IEEE 802.15.4-based protocol such as ZIGBEE transmission protocol.

5. The apparatus of claim 1 , wherein the one or more error indicators comprise one or more error flags in one or more data fields of the received data.

6. The apparatus of claim 1 , wherein the data processing unit is configured to postpone a rate of change determination when the one or more error indicators are less than the predetermined amount.

7. The apparatus of claim 1 , wherein the in vivo analyte sensor comprises a plurality of electrodes including a working electrode comprising a glucose-responsive enzyme bonded to a polymer disposed on the working electrode.

8. The apparatus of claim 7 , wherein the glucose-responsive enzyme is chemically bonded to the polymer disposed on the working electrode.

9. The apparatus of claim 7 , wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode.

10. The apparatus of claim 9 , wherein the mediator is crosslinked with the polymer disposed on the working electrode.

11. A system, comprising:

an in vivo analyte sensor positioned in contact with biofluid under a skin surface to generate analyte sensor signals corresponding to a monitored analyte level;

a transmitter unit operatively coupled to the in vivo analyte sensor to receive the analyte sensor signals and generate data corresponding to the monitored analyte level, the data including analyte data indicative of the monitored analyte level and one or more error indicators generated by the analyte sensor in response to detection of an error condition during measurement; and

a receiving device communicatively coupled to the transmitter unit, the receiving device comprising:

a data communication unit configured to wirelessly receive the data corresponding to the monitored analyte level, wherein the received data includes the analyte data and the one or more error indicators;

a memory device configured to store the received data; and

a data processing unit operatively coupled to the data communication unit and the memory device, the data processing unit configured to:

determine the monitored analyte level from the received analyte data;

determine one or more valid data points over a period of time based on the received data and the one or more error indicators;

determine a number of the one or more error indicators received over the period of time; and

determine a rate of change of the monitored analyte level based on the one or more valid data points when the number of the one or more error indicators received over the period of time are less than a predetermined amount.

12. The system of claim 11 , wherein the biofluid is interstitial fluid.

13. The system of claim 11 , wherein the analyte is either lactate or glucose.

14. The system of claim 11 , wherein the data communication unit is configured to wirelessly receive the data corresponding to the monitored analyte level using a communication protocol, the communication protocol being one of an RF communication protocol, an infrared communication protocol, or an 802.11x wireless communication protocol, or an IEEE 802.15.4-based protocol such as ZIGBEE transmission protocol.

15. The system of claim 11 , wherein the one or more error indicators comprise one or more error flags in one or more data fields of the received data.

16. The system of claim 11 , wherein the data processing unit is configured to postpone a rate of change determination when the one or more error indicators are less than the predetermined amount.

17. The system of claim 11 , wherein the in vivo analyte sensor comprises a plurality of electrodes including a working electrode comprising a glucose-responsive enzyme bonded to a polymer disposed on the working electrode.

18. The system of claim 17 , wherein the glucose-responsive enzyme is chemically bonded to the polymer disposed on the working electrode.

19. The system of claim 17 , wherein the working electrode comprises a mediator bonded to the polymer disposed on the working electrode.

20. The system of claim 19 , wherein the mediator is crosslinked with the polymer disposed on the working electrode.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: HAYTER, GARY ALAN; MCGARRAUGH, GEOFFREY V.; DONIGER, KENNETH J.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 043575/0687 →
Continuity (6)
Continuation 14741457 · Jun 17, 2015
Continuation 14106000 · Dec 13, 2013
Continuation 13599847 · Aug 30, 2012
Continuation 12152636 · May 14, 2008
Provisional Application 60917889 · May 14, 2007
Related Publication 20170340250A1 · Nov 30, 2017
Cited By (2)
US 12,315,619 US 12,390,135